This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Viral infection	Not applicable	<p><i>In vitro</i> and mouse studies suggest that the rhodanine derivative LJ001 could be useful as a small molecule broad-spectrum antiviral. In a viral infectivity assay, LJ001 inhibited the entry or spread of a panel of enveloped viruses. LJ001 rendered the viruses noninfectious by targeting their membrane and disrupting virus-cell fusion. In mice, LJ001 showed no toxicity. Next steps include optimizing LJ001 and conducting further <i>in vivo</i> studies.</p> <p>SciBX 3(6); doi:10.1038/scibx.2010.192 Published online Feb. 11, 2010</p>	<p>Patent application filed covering use as a broad-spectrum antiviral; available for licensing from the University of California, Los Angeles Office of Intellectual Property</p> <p>Contact: Lindsay Keever, University of California, Los Angeles, Calif. e-mail: LKeever@research.ucla.edu</p>	<p>Wolf, M.C. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Jan. 25, 2010; doi:10.1073/pnas.0909587107</p> <p>Contact: Benhur Lee, University of California, Los Angeles AIDS Institute, Calif. e-mail: bleebhl@ucla.edu</p>